Gabriel Mannis, MD
Medical Oncology · Stanford, CANPI 1881929347
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $141,091 of the $171,184 with a category attached, or 82.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 21.0%. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $1031.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Agios Pharmaceuticals, Inc.$23K
- Astellas Pharma Global Development$20K
- Stemline Therapeutics Inc.$18K
- Genentech USA, Inc.$15K
- Daiichi Sankyo Inc.$12K
- plus $47K from 14 others
Across 384 payments — averaging $8881.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$1.1M
- Otsuka Pharmaceutical Co., Ltd.$815K
- Taiho Oncology, Inc.$323K
- AbbVie$265K
- Bristol Myers Squibb$179K
- Syndax Pharmaceuticals, Inc.$175K
- plus $547K from 10 others
What the payments were for
- Consulting fees$141,09182%
- Speaking & faculty fees$16,28410%
- Travel & lodging$9,0895%
- Food & beverage$4,7033%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $35,910 |
| Agios Pharmaceuticals, Inc. | 19 | $22,575 |
| Astellas Pharma Global Development | 11 | $20,486 |
| Stemline Therapeutics Inc. | 15 | $18,217 |
| Genentech USA, Inc. | 11 | $14,579 |
| Daiichi Sankyo Inc. | 16 | $12,231 |
| Servier Pharmaceuticals LLC | 10 | $10,597 |
| Genentech, Inc. | 4 | $10,568 |
| Bristol Myers Squibb | 12 | $8,154 |
| Taiho Oncology, Inc. | 2 | $4,167 |
| Immunogen, Inc. | 2 | $2,940 |
| Rigel Pharmaceuticals, Inc. | 3 | $2,825 |
| Janssen Scientific Affairs, LLC | 3 | $2,659 |
| Pfizer | 1 | $1,480 |
| Jazz Pharmaceuticals Inc. | 6 | $1,402 |
| Syndax Pharmaceuticals, Inc. | 1 | $800 |
| Aadi Bioscience, Inc. | 1 | $750 |
| Astellas Pharma US Inc | 1 | $676 |
| Novartis | 3 | $142 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,184 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 18 | $588,185 |
| VenclextaVenetoclax | 57 | $380,178 |
| VanflytaQuizartinib Dihydrochloride | 11 | $297,071 |
| InqoviDecitabine/Cedazuridine | 18 | $137,451 |
| CresembaIsavuconazonium Sulfate | 11 | $67,196 |
| Allopurinol | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Servier Pharmaceuticals LLCTibsovo | $10,597 | $588,18518 claims |
| AbbVieVenclexta | $35,910 | $380,17857 claims |
| Daiichi Sankyo Inc.Vanflyta | $12,231 | $297,07111 claims |
| Taiho Oncology, Inc.Inqovi | $4,167 | $137,45118 claims |
| Astellas Pharma US IncCresemba | $676 | $67,19611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 379 medical oncology providers in California.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.